Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

NCT02280317 is registered in ClinicalTrials.gov with ValiRx Plc as lead sponsor.

NCT NCT02280317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02280317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours
Lead sponsor
ValiRx Plc
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2014
Completion date
January 27, 2020
Enrollment
12 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii prostate carcinoma, stage iv prostate carcinoma